NeoImmuneTech, Inc.
2400 Research Blvd, Suite 250
Rockville
MD
20850
United States
Tel: 240801-9067
Website: http://neoimmunetech.com/
Email: hr@neoimmunetech.com
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines.
NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials.
64 articles with NeoImmuneTech, Inc.
-
NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
8/8/2022
NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of new members of its Scientific Advisory Board.
-
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for the treatment of Glioblastoma Multiforme
7/13/2022
NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced that the U.S. Food and Drug Administration has granted NT-I7 Orphan Drug Designation for the treatment of Glioblastoma Multiforme.
-
A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
6/14/2022
NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused therapeutics company, reported that Nature Communications (Impact Factor: 14.92) published the results of an in vivo study combining the long-acting human IL-7, NT-I7, with chimeric antigen receptor (CAR) T cells directed against CD19+ B cell lymphoma and acute myeloid leukemia.
-
NeoImmuneTech to Present at Upcoming BIO International Convention
6/13/2022
NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang , Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.
-
NeoImmuneTech's Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
6/6/2022
NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.
-
NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
4/27/2022
NeoImmuneTech, Inc. today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022.
-
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
4/13/2022
Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways.
-
Money on the Move: March 9-15
3/16/2022
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates. -
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
3/10/2022
NeoImmuneTech, Inc. will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022.
-
NeoImmuneTech to Present at Upcoming Business Conferences
2/9/2022
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.
-
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers
2/7/2022
NeoImmuneTech, Inc. today announced that the first patient has been dosed in the Phase 2a portion of a study evaluating NT-I7 (efineptakin alfa).
-
Preclinical Data on NT-I7 Published in Clinical Cancer Research
1/24/2022
NeoImmuneTech, Inc. today announced the publication of preclinical data evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in mouse models of glioblastoma (GBM).
-
NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
1/5/2022
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.
-
NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
11/22/2021
NeoImmuneTech, Inc. today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.
-
NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
11/16/2021
NeoImmuneTech, Inc. today presented new data from two clinical trials evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.
-
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
11/8/2021
NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 2 study evaluating NT-I7
-
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
10/13/2021
NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 1b study of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), following CAR-T cell therapy tisagenlecleucel (Kymriah®) in patients with relapsed/refractory (r/r) Large B-Cell Lymphoma (LBCL).
-
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
10/4/2021
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 will be presented during poster sessions at the Society for Immunotherapy of Cancer annual meeting, to be held both in person in Washington, D.C. and on a virtual platform on November 10-14, 2021.
-
NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
9/13/2021
NeoImmuneTech, Inc. today announced that new data from a Phase 1/2 study evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during oral abstract sessions at the Society for Neuro-Oncology (SNO) annual meeting, to be held in Boston, Massachusetts on November 18-21, 2021.
-
NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
8/25/2021
NeoImmuneTech, Inc. today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).